Login / Signup

Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane.

Hironaga SatakeTamotsu SagawaKoshi FujikawaYukimasa HatachiHisateru YasuiMasahito KotakaTakeshi KatoAkihito Tsuji
Published in: Cancer chemotherapy and pharmacology (2018)
Salvage chemotherapy with irinotecan plus ramucirumab was well-tolerated by patients previously treated for AGC. RD was defined as irinotecan 150 mg/m2 in combination with ramucirumab 8 mg/kg.
Keyphrases
  • newly diagnosed
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • neoadjuvant chemotherapy
  • squamous cell carcinoma
  • lymph node